Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 2
1976 9
1977 9
1978 6
1979 10
1980 4
1981 10
1982 7
1983 12
1984 9
1985 9
1986 16
1987 21
1988 12
1989 25
1990 21
1991 26
1992 16
1993 13
1994 16
1995 26
1996 20
1997 14
1998 18
1999 21
2000 13
2001 19
2002 9
2003 14
2004 9
2005 11
2006 19
2007 12
2008 15
2009 14
2010 7
2011 17
2012 9
2013 15
2014 14
2015 7
2016 14
2017 10
2018 12
2019 5
2020 4
2021 12
2022 1
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

593 results

Results by year

Filters applied: . Clear all
Page 1
Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia.
Ehrmann S, Barbier F, Demiselle J, Quenot JP, Herbrecht JE, Roux D, Lacherade JC, Landais M, Seguin P, Schnell D, Veinstein A, Gouin P, Lasocki S, Lu Q, Beduneau G, Ferrandiere M, Plantefève G, Dahyot-Fizelier C, Chebib N, Mercier E, Heuzé-Vourc'h N, Respaud R, Gregoire N, Garot D, Nay MA, Meziani F, Andreu P, Clere-Jehl R, Zucman N, Azaïs MA, Saint-Martin M, Gandonnière CS, Benzekri D, Merdji H, Tavernier E; Reva and CRICS-TRIGGERSEP F-CRIN Research Networks. Ehrmann S, et al. N Engl J Med. 2023 Nov 30;389(22):2052-2062. doi: 10.1056/NEJMoa2310307. Epub 2023 Oct 25. N Engl J Med. 2023. PMID: 37888914 Clinical Trial.
RESULTS: A total of 850 patients underwent randomization, and 847 were included in the analyses (417 assigned to the amikacin group and 430 to the placebo group). All three daily nebulizations were received by 337 patients (81%) in the amikacin group and 355 patient …
RESULTS: A total of 850 patients underwent randomization, and 847 were included in the analyses (417 assigned to the amikacin group a …
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study.
Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, Addrizzo-Harris DJ, O'Donnell AE, Marras TK, Flume PA, Loebinger MR, Morgan L, Codecasa LR, Hill AT, Ruoss SJ, Yim JJ, Ringshausen FC, Field SK, Philley JV, Wallace RJ Jr, van Ingen J, Coulter C, Nezamis J, Winthrop KL; CONVERT Study Group. Griffith DE, et al. Am J Respir Crit Care Med. 2018 Dec 15;198(12):1559-1569. doi: 10.1164/rccm.201807-1318OC. Am J Respir Crit Care Med. 2018. PMID: 30216086 Clinical Trial.
Methods: Adults with amikacin-susceptible MAC lung disease and MAC-positive sputum cultures despite at least 6 months of stable GBT were randomly assigned (2:1) to receive ALIS with GBT (ALIS + GBT) or GBT alone. Once-daily ALIS was supplied in single-use vials delivering …
Methods: Adults with amikacin-susceptible MAC lung disease and MAC-positive sputum cultures despite at least 6 months of stable GBT w …
Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial.
Niederman MS, Alder J, Bassetti M, Boateng F, Cao B, Corkery K, Dhand R, Kaye KS, Lawatscheck R, McLeroth P, Nicolau DP, Wang C, Wood GC, Wunderink RG, Chastre J. Niederman MS, et al. Lancet Infect Dis. 2020 Mar;20(3):330-340. doi: 10.1016/S1473-3099(19)30574-2. Epub 2019 Dec 19. Lancet Infect Dis. 2020. PMID: 31866328 Clinical Trial.
FINDINGS: Between April 13, 2013, and April 7, 2017, 807 patients were assessed for eligibility and 725 were randomly assigned to Amikacin Inhale (362 patients) or aerosolised placebo (363 patients). 712 patients received at least one dose of study drug (354 in the Amik …
FINDINGS: Between April 13, 2013, and April 7, 2017, 807 patients were assessed for eligibility and 725 were randomly assigned to Amikaci …
Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group.
[No authors listed] [No authors listed] Arch Ophthalmol. 1995 Dec;113(12):1479-96. Arch Ophthalmol. 1995. PMID: 7487614 Clinical Trial.
INTERVENTIONS: Random assignment according to a 2 x 2 factorial design to treatment with VIT or vitreous tap or biopsy (TAP) and to treatment with or without systemic antibiotics (ceftazidime and amikacin). MAIN OUTCOME MEASURES: A 9-month evaluation of visual acuity asses …
INTERVENTIONS: Random assignment according to a 2 x 2 factorial design to treatment with VIT or vitreous tap or biopsy (TAP) and to treatmen …
Aminoglycoside ototoxicity.
Matz GJ. Matz GJ. Am J Otolaryngol. 1986 Mar-Apr;7(2):117-9. doi: 10.1016/s0196-0709(86)80040-0. Am J Otolaryngol. 1986. PMID: 3485932 Clinical Trial.
The author participated in two prospective studies of patients receiving aminoglycoside antibiotics. In the first study, 54 patients received amikacin, and 54 received gentamicin. In the second study, 61 patients received gentamicin, 50 received netilmicin, and 52 received …
The author participated in two prospective studies of patients receiving aminoglycoside antibiotics. In the first study, 54 patients receive …
A Prospective Trial of Nebulized Amikacin in the Treatment of Bronchiectasis Exacerbation.
Ailiyaer Y, Wang X, Zhang Y, Li C, Li T, Qi Q, Li Y. Ailiyaer Y, et al. Respiration. 2018;95(5):327-333. doi: 10.1159/000486134. Epub 2018 Mar 27. Respiration. 2018. PMID: 29587297 Free article. Clinical Trial.
BACKGROUND: Pseudomonas aeruginosa is the most common pathogenic bacteria in bronchiectasis (BE) patients. The availability and security of nebulized amikacin treatment are unknown. OBJECTIVE: The purpose of this study was to explore the efficiency and adverse effects of n …
BACKGROUND: Pseudomonas aeruginosa is the most common pathogenic bacteria in bronchiectasis (BE) patients. The availability and security of …
Comparison of three doses of amikacin on alternate days with a daily dose of meropenem during the same period for the treatment of urinary tract infection with E. coli: a double-blind clinical trial.
Mohsenpour B, Ahmadi A, Azizzadeh H, Ghaderi E, Hajibagheri K, Afrasiabian S, Lotfi G, Farzinpoor Z. Mohsenpour B, et al. BMC Res Notes. 2024 Jan 25;17(1):38. doi: 10.1186/s13104-023-06654-y. BMC Res Notes. 2024. PMID: 38273327 Free PMC article. Clinical Trial.
The frequency of signs and symptoms showed no significant difference between the amikacin and meropenem groups in the first 24 h and the first week. ...CONCLUSION: The results of this study showed that treatment with amikacin, 1 g q48h, for one week (three doses) ha …
The frequency of signs and symptoms showed no significant difference between the amikacin and meropenem groups in the first 24 h and …
Association between 16S rRNA gene mutations and susceptibility to amikacin in Mycobacterium avium Complex and Mycobacterium abscessus clinical isolates.
Kim SY, Kim DH, Moon SM, Song JY, Huh HJ, Lee NY, Shin SJ, Koh WJ, Jhun BW. Kim SY, et al. Sci Rep. 2021 Mar 17;11(1):6108. doi: 10.1038/s41598-021-85721-5. Sci Rep. 2021. PMID: 33731862 Free PMC article. Clinical Trial.
For the eight M. abscessus-PD patients, all amikacin-resistant (MIC 64 g/ml) isolates had rrs mutations. In amikacin-resistant isolates, the A1408G mutation (n = 29) was most common. Two novel mutations, C1496T and T1498A, were also identified. The culture conversio …
For the eight M. abscessus-PD patients, all amikacin-resistant (MIC 64 g/ml) isolates had rrs mutations. In amikacin-resistant …
Comparative effectiveness of combinations of amikacin with penicillin G and amikacin with carbenicillin in gram-negative septicemia: double-blind clinical trial.
Klastersky J, Hensgens C, Meunier-Carpentier F. Klastersky J, et al. J Infect Dis. 1976 Nov;134 SUPPL:S433-40. doi: 10.1093/infdis/135.supplement_2.s433. J Infect Dis. 1976. PMID: 792359 Clinical Trial.
Preliminary results are presented for an ongoing, double-blind, clinical trial, in which the efficacy of amikacin plus penicillin G (Amik-Pen) and amikacin plus carbenicillin (Amik-Carb) is compared in treatment of severe gram-negative infections superimposed on ser …
Preliminary results are presented for an ongoing, double-blind, clinical trial, in which the efficacy of amikacin plus penicillin G ( …
Ceftriaxone and amikacin versus ceftazidime and amikacin in febrile granulocytopenia.
Schmid L, Jeschko M, Wilder-Smith C, Schafroth U, Thürlimann B, Pedrazzini A, Senn H. Schmid L, et al. Chemotherapy. 1991;37(5):346-52. doi: 10.1159/000238878. Chemotherapy. 1991. PMID: 1804595 Clinical Trial.
The efficacy and safety of the two antibiotic combinations, ceftazidime plus amikacin and ceftriaxone plus amikacin were compared in an open randomized trial. 100 episodes of neutropenia caused by malignant diseases and/or cytostatic drugs were evaluated in 66 males …
The efficacy and safety of the two antibiotic combinations, ceftazidime plus amikacin and ceftriaxone plus amikacin were compa …
593 results